Davos WEF 2018: Downturn In Generics Won’t Last Long, Says Sun Pharma Chairman
The downturn in generic pharmaceutical business won't last long and the industry will come out of it stronger, according to Sun Pharmaceutical Industries Ltd. Chairman Israel Makov.
But while the downturn lasts, drugmakers will find several merger and acquisition opportunities, Makov told BloombergQuint's Menaka Doshi on the sidelines of the World Economic Forum 2018 at Davos, Switzerland. Indian pharma companies, already playing a role in the consolidation process, will increase their share of the generics market not only in the U.S. but also in other markets, he added.
A consolidation among pharmacies and intensifying competition have sent prices for generic drugs in the U.S., the world's largest market for medicines, into a tailspin and has left the global industry scrambling to adjust. Sun Pharma has warned that revenue this year may come in lower than the last. The world's largest generics maker Teva Pharmaceutical Industries Ltd. said it will eliminate 25 percent of its workforce and sell assets in an effort to cut costs.
Also Read: Sun Pharma Suffers as FDA Sanctions Exacerbate Generic Woes
Makov, formerly chief executive of Teva, expects the pricing pressures in the U.S. to be a temporary phenomenon. “The generics business is an important part of the healthcare industry and there is a limit for price pressures. When you exercise more price pressure, you have supply problems,” he cautioned.
Regulatory Pressures
Besides pricing, Indian drugmakers are also battling continued regulatory concerns in the form of import alerts from the U.S. drug regulator, which has hit profitability.
According to Makov, Indian industry is upgrading operations as a response to tighter regulation and increased scrutiny from the USFDA. “Yes, its a pressure, but it's a positive pressure. At the end of it, industry will produce better and more competitive products.”
Sun Pharma is waiting for USFDA re-inspection of its Halol and Kharkhadi plants.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
